Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.
Discovery | Candidate | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |||
---|---|---|---|---|---|---|---|---|
Anti Cancer |
Axl/Mer/CSF1R Inhibitor (Q702) |
Immuno Oncology |
||||||
Drug Resistant NSCLC |
||||||||
selective CDK7 inhibitor (Q901) |
Solid Tumor |
|||||||
Antibiotics | Cyt bc1 Inhibitor (Telacebec, Q203) |
Drug Resistant Tuberculosis |
||||||
COVID-19 anti-inflammation |
||||||||
Anti Inflammation |
Topical 5LO Inhibitor (Q301) |
Atopic Dermatitis |
||||||
Oral 5LO Inhibitor |
Asthma |
Candidate | Pre-Clinical | Phase 1 | Phase 2 | ||
---|---|---|---|---|---|
Axl/Mer/ CSF1R Inhibitor (Q702) |
Immuno Oncology |
||||
Drug Resistant NSCLC |
|||||
Selective CDK7 Inhibitor (Q901) |
Solid Tumor |
||||
Cytbc1 Inhibitor (Telacebec, Q203) |
Drug Resistant Tuberculosis |
||||
COVID-19 anti-inflammation |
|||||
Topical 5LO Inhibitor (Q301) |
Atopic Dermatitis |
||||
Oral 5LO Inhibitor |
Asthma |